Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2

Paclitaxel is highly efficacious in the treatment of breast, head and neck, non‐small cell lung cancers and ovarian carcinoma. For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P‐glycoprotein (P‐gp) at the blood–brain barrier. We investigated the utilization of a new drug delivery system to increase brain delivery of paclitaxel.

[1]  Paul R. Lockman,et al.  Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability , 2004, Journal of drug targeting.

[2]  M. Berger,et al.  Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. , 1999, Neuro-oncology.

[3]  J. Schellens,et al.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. , 2006, Trends in pharmacological sciences.

[4]  Michel Demeule,et al.  Identification and Design of Peptides as a New Drug Delivery System for the Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[5]  J. Tonn,et al.  EFFECTS OF DRUG EFFLUX ON CONVECTION‐ENHANCED PACLITAXEL DELIVERY TO MALIGNANT GLIOMAS: TECHNICAL NOTE , 2007, Neurosurgery.

[6]  S. Cisternino,et al.  Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats , 2003, British journal of pharmacology.

[7]  J. Crown,et al.  The taxanes: an update , 2000, The Lancet.

[8]  J. Gallo,et al.  The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. , 2003, Cancer research.

[9]  D. Begley,et al.  ABC transporters and the blood-brain barrier. , 2004, Current pharmaceutical design.

[10]  R. Himes,et al.  Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. , 2005, Journal of medicinal chemistry.

[11]  Susan M. Chang,et al.  Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. , 2006, Neurosurgical focus.

[12]  Si-Shen Feng,et al.  Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. , 2004, Current medicinal chemistry.

[13]  P. Fischer,et al.  Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin. , 2006, Bioorganic & medicinal chemistry letters.

[14]  L. Norton,et al.  Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity , 1994, International journal of clinical & laboratory research.

[15]  R. Béliveau,et al.  Inhibition of tumor growth by a truncated and soluble form of melanotransferrin. , 2007, Experimental cell research.

[16]  Michel Demeule,et al.  High transcytosis of melanotransferrin (P97) across the blood–brain barrier , 2002, Journal of neurochemistry.

[17]  P. Borst,et al.  Multidrug resistance and the role of P-glycoprotein knockout mice. , 1995, European journal of cancer.

[18]  Christophe Rousselle,et al.  Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  P. Gaillard,et al.  Targeted delivery across the blood–brain barrier , 2005, Expert opinion on drug delivery.

[20]  T. Budinger,et al.  Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[21]  David N Louis,et al.  Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.

[22]  C. Rousselle,et al.  New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. , 2000, Molecular pharmacology.

[23]  R. Mumper,et al.  Paclitaxel nanoparticles for the potential treatment of brain tumors. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[24]  R. Geney,et al.  Overcoming Multidrug Resistance in Taxane Chemotherapy , 2002, Clinical chemistry and laboratory medicine.

[25]  E. Shusta,et al.  Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.

[26]  W. Rose.  Taxol: a review of its preclinical in vivo antitumor activity. , 1992, Anti-cancer drugs.

[27]  Willem Boogerd,et al.  Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? , 2004, Cancer treatment reviews.

[28]  W. Löscher,et al.  The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses , 2007, Clinical Cancer Research.

[29]  J. Verweij,et al.  Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  M. Chamberlain,et al.  Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Claudia J. Bode,et al.  Understanding tubulin–Taxol interactions: Mutations that impart Taxol binding to yeast tubulin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Chamberlain,et al.  Salvage Chemotherapy with Taxol for Recurrent Anaplastic Astrocytomas , 1999, Journal of Neuro-Oncology.

[33]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[34]  J. Temsamani,et al.  Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel , 2004, Anti-cancer drugs.

[35]  Armin Buschauer,et al.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. , 2002, The Journal of clinical investigation.

[36]  K. Walter,et al.  Cytotoxicity of taxol in vitro against human and rat malignant brain tumors , 2004, Cancer Chemotherapy and Pharmacology.

[37]  William Couet,et al.  Indirect Evidence that Drug Brain Targeting Using Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles Is Related to Toxicity , 1999, Pharmaceutical Research.

[38]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[39]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[40]  Raphael Pfeffer,et al.  Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. , 2004, Journal of neurosurgery.